Table 1.
Patient characteristics
| Number | Gender, age (years) | EGFR mutation (TKI sensitivity) | Response to erlotiniba | [11C]Erlotinib PET scans | Condition | Arterial sampling | Venous sampling | [15O]H2O PET scans | Remarks |
|---|---|---|---|---|---|---|---|---|---|
| Change in V T b | Time interval to second scan (days) | ||||||||
| 1 | F | exon19 (p.delE746-A750) and exon20 (T790M) | PD | First scan | E+ | Yes | Yes | Yes | |
| 60 | (sensitive + resistant) | – | Second scan | E− | NA | NA | NA | Synthesis of [11C]erlotinib failed quality check | |
| 7 | |||||||||
| 2 | F | exon19 (p.delE746-A750) | CR | First scan | E− | Yes | Yes | Yes | |
| 82 | (sensitive) | −52 % | Second scan | E+ | Yes | NA | Yes | No venous sampling due to clogging of the venous cannula | |
| 14 | |||||||||
| 3 | M | exon18 (p.G719S and p.E709A) | PR | First scan | E− | Yes | Yes | Yes | |
| 74 | (sensitive [22, 23]) | −17 % | Second scan | E+ | Yes | Yes | NA | Synthesis of [15O]H2O failed quality check | |
| 13 | |||||||||
| 4 | M | exon21 (p.P848L) | – | First scan | E− | Yes | Yes | Yes | |
| 66 | (resistant [24]) | −43 % | Second scan | E+ | Yes | Yes | Yes | ||
| 7 | |||||||||
| 5 | F | exon19 (p.delE746-T751) (sensitive) | PD | First scan | E+ | Yes | Yes | NA | Synthesis of [15O]H2O failed quality check |
| 61 | – | Second scan | NA | NA | NA | NA | Yield of [11C]erlotinib synthesis too low | ||
| 7 | |||||||||
| 6 | F | exon19 (p.delE746-A750) and exon20 (p.T790M) | Slow PD | First scan | E+ | Yes | Yes | Yes | |
| 45 | (sensitive + resistant) | −47 % | Second scan | E− | Yes | Yes | Yes | ||
| 10 | |||||||||
| 7 | M | exon19 (p.E746-S752) and exon20 (p.T790M) | SD | First scan | E− | NA | NA | NA | Aberrant arterial and venous blood sample values |
| 74 | (sensitive + resistant) | – | Aberrant [15O]H2O PET data | ||||||
| Second scan | E+ | Yes | Yes | Yes | |||||
| 7 | |||||||||
| 8 | M | exon18 (p.G719S) and exon20 (p.S768I) | SD | First scan | E− | Yes | Yes | Yes | |
| 81 | (unclear [25, 26, 27]) | −58 % | Second scan | E+ | Yes | Yes | Yes | ||
| 7 | |||||||||
| 9 | F | exon19 (p.delE746-A750) | PR | First scan | E− | Yes | Yes | Yes | Aberrant [15O]H2O PET data |
| 55 | (sensitive) | −29 % | Second scan | E+ | Yes | Yes | Yes | ||
| 10 | |||||||||
| 10 | F | exon19 (p.delL747-S752 and p.P753Q) and exon20 (p.T790M) | Slow PD | First scan | E+ | Yes | Yes | NA | No [15O]H2O synthesis |
| 71 | (sensitive + resistant) | −25 % | Second scan | E− | Yes | Yes | NA | No [15O]H2O synthesis | |
| 14 | |||||||||
| 11 | F | exon21 (p.L861Q) | SD | First scan | E− | Yes | Yes | Yes | |
| 77 | (sensitive [28]) | −39 % | Second scan | E+ | Yes | Yes | NA | No [15O]H2O synthesis | |
| 7 | |||||||||
| 12 | M | exon19 (p.delE746 S752) | PR | First scan | E− | Yes | Yes | Yes | |
| 70 | (sensitive) | – | Second scan | NA | NA | NA | NA | Yield of [11C]erlotinib synthesis too low | |
| 7 | |||||||||
| 13 | F | exon21 (p.L858R) and exon20 (p.T790M) | Slow PD | First scan | E− | Yes | Yes | Yes | |
| 74 | (sensitive + resistant) | −40 % | Second scan | E+ | Yes | Yes | Yes | ||
| 7 |
Abbreviations: F female, M male, E+ with erlotinib therapy, E− without erlotinib therapy, CR complete response, PR partial response, SD stable disease, PD progressive disease, NA not available
aTumor response to erlotinib as evaluated at the time of the first scan (in patients stopping erlotinib) or tumor response to erlotinib after its initiation (in patients starting erlotinib therapy)
bChange in V T as defined by (V T(E+) − V T(E−)) / V T(E−)